The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

COVID-19 was associated with more severe disease outcomes than influenza or respiratory syncytial virus (RSV) during ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

U.S. surges of COVID-19, influenza, respiratory syncytial virus (RSV) and norovirus have collectively been dubbed a ...

COVID-19 has been more prevalent and has caused more deaths than flu or respiratory syncytial virus (RSV) in the last three years, according to a study on American veterans published Monday in JAMA ...

RSV is usually contagious for three to eight days. A patient also may be contagious a day or two before experiencing symptoms ...

Respiratory Syncytial Virus (RSV) is a highly contagious respiratory illness that primarily affects infants and older adults, ...

Four viruses are circulating in the U.S., sparking concerns of a possible “quademic." Here's what to know about risk factors ...

The Health Protection Surveillance Centre (HPSC) has reported a further reduction in cases of flu, the Respiratory Syncytial ...

The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...

Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

It warned of illnesses including flu, Covid, RSV, norovirus, the less familiar hMPV and, of course, the common cold. With these viruses proving to be highly infectious and spreading rapidly, the UKHSA ...